DR.CYJ Hair Filler is one of the most clinically distinctive injectable treatments available for hair loss. Unlike conventional mesotherapy cocktails that rely on nutrient delivery alone, DR.CYJ uses a patented Polypeptide Complex of seven biomimetic peptides specifically developed to target the underlying biological mechanisms of androgenetic alopecia, scalp damage, and hair follicle miniaturisation. This guide gives practitioners everything they need to confidently integrate DR.CYJ into their practice: formulation, mechanism of action, injection protocol, treatment scheduling, side effects, expected outcomes, and patient selection.

What Is DR.CYJ Hair Filler?

DR.CYJ Hair Filler is an injectable treatment developed by Caregen (South Korea), a company specialising in biomimetic peptide technology. The product is indicated for hair loss and scalp health across multiple aetiology types and is specifically designed for intradermal and subcutaneous scalp injection.

Each vial contains 1 ml of a proprietary formulation combining:

  • Polypeptide Complex (PC): a blend of 7 biomimetic peptides targeting DHT activity, hair follicle cell proliferation, growth factor stimulation, and scalp microcirculation
  • Hyaluronic acid base: low-concentration HA (non-cross-linked) providing a vehicle for product delivery, scalp hydration, and improved injectability
  • Adenosine: a recognised hair growth active that prolongs the anagen (growth) phase of the hair cycle
  • Biotin (Vitamin B7): a key cofactor in keratin synthesis, supporting hair shaft strength

The combination of peptide-mediated biostimulation and supporting actives distinguishes DR.CYJ from single-ingredient hair loss injectables and standard mesotherapy cocktails.

Licensed practitioners can order DR.CYJ Hair Filler at wholesale prices from Bioresus at the DR.CYJ Hair Filler product page.

The Polypeptide Complex: Mechanism of Action

The core scientific differentiation of DR.CYJ is its 7-peptide Polypeptide Complex. Each peptide targets a specific pathway involved in hair follicle biology:

1. Biotinoyl Tripeptide-1

Mimics the effect of biotin on hair follicle anchorage. Strengthens the connection between the hair follicle and the dermal papilla, reducing follicle detachment — a key early event in androgenetic alopecia.

2. Acetyl Tetrapeptide-3

Stimulates the extracellular matrix proteins laminin and collagen IV at the dermal-epidermal junction, improving follicle anchoring and overall scalp tissue health.

3. Oligopeptide-54

Directly promotes the proliferation of dermal papilla cells — the cells in the hair follicle bulb that drive hair growth. Stimulates Wnt/beta-catenin signalling, a critical pathway for anagen phase initiation.

4. Oligopeptide-71

Inhibits 5-alpha reductase activity, reducing the local conversion of testosterone to dihydrotestosterone (DHT) in the scalp. DHT is the primary androgen driving follicle miniaturisation in androgenetic alopecia.

5. Decapeptide-18

Increases the expression of KGF (keratinocyte growth factor) in dermal papilla cells, promoting keratinocyte proliferation and differentiation and supporting the integrity of the hair follicle structure.

6. Oligopeptide-41

Promotes vascularisation around hair follicles through VEGF (vascular endothelial growth factor) stimulation, improving oxygen and nutrient delivery to the follicle bulb and supporting sustained anagen phase.

7. Acetyl Hexapeptide-1

Has melanogenesis-stimulating activity, supporting melanocyte function in the hair follicle matrix. May contribute to delaying premature greying associated with follicle stress.

The combined action of these seven peptides on five distinct biological targets (DHT inhibition, follicle anchoring, dermal papilla cell proliferation, vascularisation, and growth factor stimulation) makes DR.CYJ mechanistically more targeted than standard mesotherapy.

Clinical Indications

Primary Indications

  • Androgenetic alopecia (AGA) in men and women: the primary indication. DR.CYJ targets DHT-mediated follicle miniaturisation and promotes dermal papilla cell proliferation in affected follicles
  • Telogen effluvium: stress-induced, post-partum, or illness-related diffuse hair shedding. The peptide complex supports anagen re-entry and strengthens recovering follicles
  • Chemical and thermal damage: DR.CYJ addresses subcutaneous tissue damage in the scalp caused by repeated chemical processing or heat styling that compromises follicle health
  • Alopecia areata (adjunct): can be used as an adjunct treatment alongside primary therapy in stable, localised alopecia areata to stimulate surrounding follicles
  • Post-surgical hair growth disorders: follicle disruption following scalp surgery or hair transplantation
  • General hair thinning and density reduction: patients with early-stage hair thinning seeking a preventive and restorative injectable option

Contraindications

  • Known hypersensitivity to any component of the formulation
  • Active scalp infection, folliculitis, or dermatitis at the proposed injection site
  • Pregnancy and breastfeeding
  • Active autoimmune alopecia in an unstable, rapidly progressing phase
  • Scalp psoriasis with active plaques at the injection site
  • Patients on anticoagulants (relative contraindication; increased bleeding/bruising risk)

DR.CYJ Hair Filler Dosage and Treatment Protocol

Standard Treatment Protocol

  • Recommended course: 10 sessions over 10-12 weeks (weekly or bi-weekly injections)
  • Volume per session: 1 vial (1 ml per session) for targeted treatment; up to 2 vials (2 ml) for diffuse alopecia affecting the entire scalp
  • Maintenance: 1 session per month after completing the initial course, or 1 session every 6-8 weeks for long-term stabilisation

Accelerated Protocol (Moderate-to-Severe Alopecia)

  • Weekly sessions for the first 4 weeks
  • Bi-weekly sessions for weeks 5-12
  • Monthly maintenance thereafter

Preventive and Maintenance Protocol (Mild Thinning)

  • One session every 2-4 weeks for 4-6 sessions as an initial course
  • Monthly maintenance

Injection Technique

Equipment

  • 30-32G needle (short, 4-6 mm length) for intradermal injection
  • 25-27G needle for subcutaneous injection in areas of thicker scalp tissue
  • DR.CYJ Hair Filler 1 ml vial (prefilled syringe or vial depending on pack format)
  • Sterile gloves
  • Antiseptic scalp preparation (70% isopropyl alcohol or chlorhexidine spray)
  • Optional: topical anaesthetic (EMLA cream) or scalp block with lignocaine for patient comfort

Injection Approaches

Papule / Microinjection Technique (most commonly used):

  • Multiple intradermal injections placed 1-1.5 cm apart across the treatment zone
  • Depth: 2-3 mm (superficial dermis to mid-dermis) for maximum contact with follicle-associated cells
  • Volume per injection point: 0.02-0.05 ml
  • Total injection points: 20-40 per session depending on the treatment area size

Nappage Technique (for diffuse alopecia):

  • Rapid, multiple very superficial injections across the entire affected scalp area
  • Needle bevel up, 30-45 degree angle
  • Suitable for treating large areas efficiently

Linear Threading (for targeted bald patches or defined areas):

  • Retrograde injection of small threads of product along the direction of hair growth
  • Effective for localised density reduction and post-surgical areas

Treatment Zone Mapping

  • Divide the scalp into anatomical zones: frontal, mid-scalp (vertex), temporal, and crown
  • Concentrate injections in the areas of greatest clinical concern based on patient history and clinical assessment
  • For AGA in men: focus on the vertex and mid-scalp initially; extend to the hairline zone in the second course
  • For diffuse telogen effluvium: treat the entire scalp systematically

Post-Injection Care

  • Advise patients to avoid washing hair for 12-24 hours post-treatment
  • Avoid vigorous scalp massage, heavy exercise, and saunas for 24 hours
  • Mild erythema and small injection papules at treatment sites are expected and resolve within hours
  • Patients may resume normal hair care routines from the following day

Expected Clinical Outcomes

Timeline of Results

  • Sessions 1-3 (Weeks 1-3): Scalp condition improvement, reduced shedding reported by some patients, improved scalp hydration and reduced follicle inflammation
  • Sessions 4-7 (Weeks 4-7): Reduction in active hair shedding, vellus hair regeneration beginning in previously thinning areas, improved hair fibre strength
  • Sessions 8-10 (Weeks 8-12): Measurable improvement in hair density and coverage; new terminal hairs emerging in previously miniaturised follicles; patient satisfaction typically peaks at this stage
  • Month 4-6: Continued density improvement as previously dormant follicles complete their anagen re-entry cycle

Clinical Evidence

Clinical studies on Caregen’s Polypeptide Complex have demonstrated:

  • Significant reduction in hair shedding (measured by the pull test and standardised trichoscopy) after 10-session courses
  • Increase in anagen-phase hair percentage in treated areas compared to untreated controls
  • Improvement in scalp condition scores including sebum balance, hydration, and follicle inflammation markers

Outcomes depend on alopecia type, severity, duration, patient age, and compliance with the full treatment course. AGA patients in early-to-moderate stages respond best. Patients with long-standing severe follicle miniaturisation or fibrotic alopecia are less likely to achieve significant regrowth.

DR.CYJ vs Other Hair Loss Injectable Treatments

  • DR.CYJ vs standard mesotherapy cocktails: Standard mesotherapy uses nutrient solutions (vitamins, minerals, amino acids) delivered to the scalp without targeted peptide biostimulation. DR.CYJ’s Polypeptide Complex specifically targets DHT, dermal papilla proliferation, follicle anchoring, and vascularisation, making it mechanistically more targeted than generic mesotherapy.
  • DR.CYJ vs Polynucleotide hair treatments (e.g., Plinest Hair, Nucleofill Hair): Polynucleotide-based hair treatments stimulate tissue regeneration and reduce scalp inflammation via DNA repair mechanisms. DR.CYJ targets hair follicle biology more directly through DHT inhibition and growth factor pathways. Both can be used in combination or sequenced for enhanced outcomes.
  • DR.CYJ vs topical minoxidil: Minoxidil is a vasodilator applied topically; its precise hair growth mechanism is not fully understood. DR.CYJ delivers peptide actives directly to follicle-level tissue depth, bypassing the poor dermal penetration of topical products. The two can be used concurrently and may have additive effects.
  • DR.CYJ vs oral finasteride: Finasteride is a systemic 5-alpha reductase inhibitor with well-known systemic side effects. DR.CYJ’s Oligopeptide-71 offers localised 5-alpha reductase inhibition at the scalp level without systemic DHT suppression, making it suitable for patients who cannot or will not take finasteride.

Patient Selection and Counselling

Ideal Candidates

  • Adults with Norwood Grade I-IV AGA (men) or Ludwig Grade I-II AGA (women)
  • Patients with telogen effluvium lasting more than 3 months
  • Patients seeking an injectable treatment to complement or replace topical products
  • Patients who have declined or cannot tolerate oral finasteride or dutasteride
  • Patients who have undergone hair transplantation and wish to support surrounding native hair follicles

Less Suitable Candidates

  • Patients with Norwood Grade VI-VII AGA with extensive, long-standing bald areas (follicle regeneration is unlikely)
  • Patients expecting results within 2-4 weeks (the treatment requires patience and course completion)
  • Patients unwilling to commit to the initial 10-session protocol

Key Counselling Points

  • DR.CYJ Hair Filler works to slow progression, reduce shedding, and stimulate regrowth in viable follicles — it cannot regrow hair from permanently destroyed follicle units
  • Results require completing a full treatment course; partial courses yield limited benefit
  • Hair growth is a slow biological process; visible regrowth typically takes 3-6 months from start of treatment
  • Monthly maintenance injections are required after the initial course to sustain results
  • Combining DR.CYJ with evidence-based topical treatments (minoxidil) and healthy hair practices improves outcomes

Integrating DR.CYJ into a Comprehensive Hair Loss Service

DR.CYJ Hair Filler works best as part of a multi-modal hair loss management approach. Practitioners offering a comprehensive hair loss service may consider pairing DR.CYJ with:

  • Scalp health assessment tools: trichoscopy, standardised photography, and patient hair shedding diaries establish a documented baseline and allow objective monitoring of response
  • Topical minoxidil (foam or solution): synergistic with DR.CYJ and appropriate for most AGA patients as a maintenance strategy between injectable sessions
  • PRP (platelet-rich plasma) therapy: PRP and DR.CYJ can be alternated or combined for enhanced growth factor stimulation in patients with moderate-to-severe alopecia
  • Nutritional supplementation: biotin, iron, zinc, and vitamin D supplementation addresses underlying deficiency-related shedding that may be compounding AGA

For practitioners already offering aesthetic skin treatments such as polynucleotide injections, adding DR.CYJ Hair Filler to the service menu allows the same biostimulatory principles to be applied to scalp health, expanding the practice into the growing medical hair loss market.

Ordering DR.CYJ Hair Filler Wholesale

Licensed practitioners can order DR.CYJ Hair Filler at wholesale prices from Bioresus. Browse the DR.CYJ brand page and the full mesotherapy range for additional hair treatment options. All products are sourced from authorised distributors with full documentation.

Conclusion

DR.CYJ Hair Filler represents a significant step forward from traditional mesotherapy for hair loss. Its 7-peptide Polypeptide Complex targets the core biological processes driving androgenetic alopecia and other hair loss types with a precision that generic nutrient cocktails cannot match. For practitioners looking to build a credible, evidence-supported hair loss injectable service, DR.CYJ offers a clinically distinctive product with a well-defined protocol, strong patient satisfaction data, and a clear mechanistic rationale that supports confident patient counselling.